Soft Tissue Sarcomas of the Foot and Ankle: Impact of Unplanned Excision, Limb Salvage, and Multimodality Therapy

2008 ◽  
Vol 29 (7) ◽  
pp. 690-698 ◽  
Author(s):  
Mihir M. Thacker ◽  
Benjamin K. Potter ◽  
J David. Pitcher ◽  
H Thomas. Temple
2010 ◽  
Vol 92-B (3) ◽  
pp. 424-429 ◽  
Author(s):  
G. L. Cribb ◽  
S. C. S. Loo ◽  
I. Dickinson

Author(s):  
Katherine E. Mallett ◽  
Matthew T. Houdek ◽  
Rachel L. Honig ◽  
Karim Bakri ◽  
Peter S. Rose ◽  
...  

2020 ◽  
Vol 54 (6) ◽  
pp. 372-376
Author(s):  
Hideki Tokumoto ◽  
Shinsuke Akita ◽  
Yoshitaka Kubota ◽  
Nobuyuki Mitsukawa

2020 ◽  
pp. 107110072095208
Author(s):  
Arvind S. Narayanan ◽  
Kempland C. Walley ◽  
Todd Borenstein ◽  
G. Aman Luther ◽  
J. Benjamin Jackson ◽  
...  

Although necrotizing fasciitis is a life-threatening entity that needs expeditious treatment, cases involving the lower extremity are less commonly encountered than in the upper extremity. Surgical intervention is often required and likely lead to amputation (below-knee or above-knee) vs debridement in the lower extremity. Coverage options in the foot and ankle after serial debridements can present many challenges for limb salvage. Patients are often left with large soft tissue defects requiring coverage with a subsequent increase in relative morbidity. Treatment options for coverage in these cases include negative-pressure wound therapy, split-thickness skin grafting, free flap coverage, or higher-level amputation. In the diabetic population, who present with a lower extremity necrotizing infection, limb salvage is often a challenge given the multiple comorbidities associated with these patients including peripheral vascular disease, immunocompromised state, and neuropathy. Optimal treatment strategies for these necrotizing infections in the foot and ankle remain uncertain. We offer a technique tip for utilization of a dermal regeneration matrix to allow coverage of large soft tissue defect with exposed tendon and/or bone without the need for free flap coverage or higher-level amputation, thus allowing for an additional limb salvage option. Level of Evidence: Level V, expert opinion.


2016 ◽  
Vol 2016 ◽  
pp. 1-8
Author(s):  
Hina Saeed ◽  
David M. King ◽  
Candice A. Johnstone ◽  
John A. Charlson ◽  
Donald A. Hackbarth ◽  
...  

Background. The management for unplanned excision (UE) of soft tissue sarcomas (STS) has not been established. In this study, we compare outcomes of UE versus planned excision (PE) and determine an optimal treatment for UE in STS.Methods. From 2000 to 2014 a review was performed on all patients treated with localized STS. Clinical outcomes including local recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) were evaluated using the Kaplan-Meier estimate. Univariate (UVA) and multivariate (MVA) analyses were performed to determine prognostic variables. For MVA, Cox proportional hazards model was used.Results. 245 patients were included in the analysis. 14% underwent UE. Median follow-up was 2.8 years. The LR rate was 8.6%. The LR rate in UE was 35% versus 4.2% in PE patients (p<0.0001). 2-year PFS in UE versus PE patients was 4.2 years and 9.3 years, respectively (p=0.08). Preoperative radiation (RT) (p=0.01) and use of any RT for UE (p=0.003) led to improved PFS. On MVA, preoperative RT (p=0.04) and performance status (p=0.01) led to improved PFS.Conclusions. UEs led to decreased LC and PFS versus PE in patients with STS. The use of preoperative RT followed by reexcision improved LC and PFS in patients who had UE of their STS.


2020 ◽  
Vol 34 ◽  
pp. 212-217
Author(s):  
Guido Scoccianti ◽  
Matteo Innocenti ◽  
Filippo Frenos ◽  
Francesco Muratori ◽  
Federico Sacchetti ◽  
...  

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 11051-11051
Author(s):  
Samer Salah ◽  
Anthony Lott ◽  
Peter Charles Ferguson ◽  
Jay Wunder ◽  
Abha A. Gupta ◽  
...  

Sarcoma ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Daniel Friedmann ◽  
Jay S. Wunder ◽  
Peter Ferguson ◽  
Brian O'Sullivan ◽  
David Roberge ◽  
...  

Background and Purpose. Lymphoedema is a serious complication following limb salvage for extremity soft tissue sarcomas (STSs) for which little is known. We aimed to evaluate its incidence, its, severity and its associated risk factors.Material and Method. Patient and tumor characteristics, treatment modalities and complications and functional outcomes (MSTS 1987, TESS), and lymphoedema severity (Stern) were all collected from prospective databases. Charts were retrospectively abstracted for BMI and comorbidities.Results. There were 289 patients (158 males). Mean age was 53 (16–88). Followup ranged between 12 and 60 months with an average of 35 and a median of 36 months. Mean BMI was 27.4 (15.8–52.1). 72% had lower extremity tumors and 38% upper extremity. Mean tumor size was 8.1 cm (1.0–35.6 cm). 27% had no adjuvant radiation, 62% had 50 Gy, and 11% received 66 Gy. The incidence of lymphoedema was 28.8% (206 none, 58 mild, 22 moderate, 3 severe, and 0 very severe). Mean MSTS score was 32 (11–35) and TESS was 89.4 (32.4–100). Radiation dose was significantly correlated with tumorsize>5 cm (P=0.0001) and TESS score (P=0.001), but not MSTS score (P=0.090). Only tumorsize>5 cm and depth were found to be independent predictors of significant lymphoedema.Conclusion. Nine percent of STS patients in our cohort developed significant (grade≥2) lymphoedema. Tumorsize>5 cm and deep tumors were associated with an increased occurrence of lymphoedema but not radiation dosage.


Sign in / Sign up

Export Citation Format

Share Document